DA
ALGS icon

Denali Advisors’s Aligos Therapeutics ALGS Stock Holding History

Denali Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-640
Closed -$34K – 379
2022
Q1 		$34K Buy
+640
New +$51.3K 0.01% 278

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Denali Advisors's ALGS Position: Q2 2022 in Review

Denali Advisors sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 640 shares — an estimated $34K sold.

Denali Advisors first reported a position in ALGS in Q1 2022 and held it in 1 quarter. The position peaked at $34K in Q1 2022. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

  • Denali Advisors reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Denali Advisors sold 640 Aligos Therapeutics shares in Q2 2022, an estimated $34K.
  • Denali Advisors first reported a position in Aligos Therapeutics in Q1 2022 and held it in 1 quarter.
  • Denali Advisors's Aligos Therapeutics position peaked at $34K in Q1 2022.
  • 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on Denali Advisors's 13F filing for Q2 2022, filed 18 Jul 2022.